Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. According to the agreement, CSPC will receive a $7.5m

Antibody 130

Antibody Drugs Clinical Development Licensing 130

pharmaphorum

APRIL 27, 2022

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 billion with no sales recorded in the prior year.

Sales 95

Sales Antibody Vaccination Vaccine 95

Pharmaceutical Technology

MAY 15, 2023

Sanofi announced data from a real-world clinical trial that demonstrated its RSV antibody nirsevimab delivered an 83% reduction in hospitalisations in infants with respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). Nirsevimab is being jointly developed between Sanofi and AstraZeneca.

Antibody 245

Antibody Vaccination Vaccine Trials 245

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy.

Drugs 264

Drugs Sales Antibody Dermatology 264

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

Drug Discovery World

MAY 7, 2024

In this webinar, you will hear from Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader – Scientific Solutions Consulting at Benchling, and Dr Paola Genevini, Technical Sales Specialist at Bio-Rad.

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Roots Analysis

FEBRUARY 27, 2024

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period.

Antibody 40

Antibody Marketing Drugs Contract Manufacturing 40

Drug Discovery World

APRIL 8, 2024

Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. Dr Levy will outline the significance of belimumab, a monoclonal antibody that inhibits B-cell activating factor. What effect has antibody engineering had on drug discovery and development?

Antibody 59

Antibody Marketing Gene Therapy Engineer 59

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

Drug Discovery World

APRIL 22, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Development Gene Therapy Marketing 52

Drug Discovery World

APRIL 29, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

XTalks

DECEMBER 19, 2023

In the fast-evolving pharmaceutical landscape, tracking the top-selling drugs offers valuable insights into trends, healthcare priorities and the dynamics of the global market. As we approach the end of 2023, a retrospective look at the statistics from 2022 reveals the top 20 drugs dominating retail sales.

Sales 64

Sales FDA Approval Drugs Vaccination 64

pharmaphorum

OCTOBER 6, 2022

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4

Sales 97

Sales Drugs Branding Antibody 97

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Drug Discovery World

SEPTEMBER 12, 2023

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono.

Antibody 72

Antibody Sales Production Development 72

BioSpace

OCTOBER 26, 2023

billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3

Sales 119

Sales Antibody Drugs 119

Bio Pharma Dive

MAY 4, 2022

revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.

Sales 146

Sales Antibody Drugs Marketing 146

Pharmaceutical Technology

NOVEMBER 21, 2022

Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs. As per the partnership, Nona will offer Dragonfly access to its HCAb technologies and antibody generation services for the targets chosen by the latter.

Antibody 130

Antibody Drugs Engineer Sales 130

Drug Discovery World

SEPTEMBER 6, 2023

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature. In 2022, there were 156 antibody-focused deals with a value of $57.3 Reference [link] The post Antibody development drives high-value biotech deals appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Sales Manufacturing 52

Roots Analysis

OCTOBER 25, 2023

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5

Antibody 40

Antibody Development Drugs Marketing 40

Fierce Pharma

MARCH 7, 2024

GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.

Antibody 100

Antibody Sales Trials Medicine 100

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The post Atomwise and Sanofi partner for drug discovery using AI appeared first on Pharmaceutical Technology.

Drugs 246

Drugs Engineer Medicine Sales 246

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130

STAT News

MARCH 13, 2023

Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43 billion. The deal helps Pfizer, flush with cash but in need of new sources of revenue due to declining sales of Covid treatments, by adding a lineup of cancer drugs called antibody-drug conjugates that work by delivering chemotherapy directly to tumors.

Drugs 105

Drugs Sales Antibody 105

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4

Antibody 145

Antibody Vaccination Vaccine Drugs 145

Pharmaceutical Technology

JUNE 15, 2023

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.

Antibody 130

Antibody Sales Protein Development 130

Drug Discovery World

JANUARY 11, 2023

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . The post Collaboration to identify up to 10 novel target-antibody pairs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Engineer Immune Response Sales 52

XTalks

SEPTEMBER 7, 2021

After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, new data shows that while those variants may be resistant to the drugs, the currently dominating Delta variant may not be. 1 and Beta/B.1.351,

Antibody 97

Antibody In-Vitro Drugs Sales 97

pharmaphorum

NOVEMBER 6, 2022

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. However, revenues from the antibody are expected to drop sharply once Beyfortus and vaccines for RSV prevention enter the market.

Antibody 62

Antibody Vaccination Vaccine Sales 62

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Vaccination 272

Vaccination Vaccine Sales Generic Drugs 272

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6

Sales 101

Sales Production Vaccination Vaccine 101

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Drug Discovery World

APRIL 29, 2024

The last couple of months has seen a number of changes in senior roles in the drug discovery sector. He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

OCTOBER 21, 2022

billion, plus royalties on net sales. Zanidatamab is a HER2-targeted bispecific antibody with novel mechanisms of action. In BTC, the US Food and Drug Administration (FDA) has granted it Breakthrough Therapy designation. In BTC, the US Food and Drug Administration (FDA) has granted it Breakthrough Therapy designation.

Antibody 52

Antibody Licensing Licensing Sales 52